# Altay raises $37 million for muscular dystrophy drug development

_Published Thursday, October 15, 2026 at 5:19 PM EDT · Capital · Latest · Tier 2 — Notable_

![Altay raises $37 million for muscular dystrophy drug development — Primary](https://s.yimg.com/lo/mysterio/api/15cc4764e11e3ccd4c8c3127a222536aa4e2bae13a74a861beb5ae6c20605651/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fbusiness-wire.com%2F8f05bfb31bd718800412438fc28c606b.jpg)

Altay Therapeutics announced a $37 million Series A financing co-led by Sound Bioventures and HealthCap. The company plans to use the proceeds to advance DX5057 through Phase 1 and Phase 2 proof-of-concept trials for facioscapulohumeral muscular dystrophy, or FSHD.

DX5057 is an oral small molecule designed to inhibit DUX4, a protein that regulates gene activity and whose abnormal expression in skeletal muscle drives FSHD. Altay expects to begin a Phase 1 safety study in Q1 2027. The clinical program will examine DUX4-related biomarkers and muscle function.

## Sources

- [Yahoo Finance](https://finance.yahoo.com/healthcare/articles/altay-therapeutics-closes-37-million-120000212.html)

---
Canonical: https://techandbusiness.org/newswire/08sB0MH1dC_sdRGZY_14QF
Published: 2026-10-15T21:19:07.267Z
Story chronology: 2026-10-14T12:00:00.000Z
Retrieved: 2026-10-15T23:44:53.254Z
Publisher: Tech & Business (techandbusiness.org)